Bum-Yong Kang PhD
Overview
Bum-Yong Kang, Ph.D. is an Assistant Professor of Medicine and Principle Investigator (PI) at Emory Universitys Department of Medicine in the Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine. In 2010, he was first awarded research funding as an independent PI from the Childrens Center for Endothelial Biology. In January 2013, Dr. Kang received the National Scientist Development Grant from the American Heart Association, which is currently ongoing.
For more than 10 years, Dr. Kang has extensively trained in a number of academic research areas, including molecular population genetics, functional genomics using microarray and proteomic analysis, and microRNA analysis. Through two different institutional postdoctoral trainings, Dr. Kang became an expert data analyst on molecular functional genomics employing bioinformatic techniques. One major research area is molecular population genetics in which Dr. Kang trained and received his Ph.D. degree in 2002 from Seoul National University, South Korea. Another research area is functional genomics using microarray and proteomics as postdoctoral fellowship trainings in the Department of Biology at Dalhousie University, Canada from 2004-2005 and in the Department of Medicine at University of Arkansas for Medical Sciences (UAMS), U.S.A. from 2006-2009 until he was recruited to Emory University in 2009. Since 2009, Dr. Kang has intensively investigated novel approach microRNA analysis in pathogenesis of pulmonary hypertension (PH), leading not only to successful intra-institutional collaboration but also to research funding to elucidate the role of microRNA of human diseases.
Currently, Dr. Kangs research career focuses on the examination of the mechanisms of pulmonary hypertension with sickle cell disease. Early in his research career and while still a postdoctoral fellow in UAMS he made several sentinel findings of the role of LOX-1 in hypertension and atherosclerosis. After moving to Emory in 2009, his research is extended from heart to lungs, and then he became interested in the ET-1 signaling pathway and its role in PH. Most recently, he has extended his novel work on pulmonary vascular biology to the field of hypoxia-induced PH and sickle cell disease with PH (SCD-PH). His work employs novel animal models of human pulmonary vascular disease to study the role of PPAR in the development of PH. His most recent research career focuses on exploring how PPAR activation regulates microRNAs that modulate hypoxia-induced ET-1 signaling in the pathogenesis of PH.
Dr. Kangs long-term research goal is to create his own model in the pathogenesis of SCD-PH; how does pulmonary vascular remodeling generate in the pulmonary vasculature? To elucidate this question, this model will use integratedOMICS data: functional genomics, proteomics, microRNAs, and metabolomics analysis, lead not only to identifying innovative approaches to the treatment of pulmonary vascular disease, but also to clarifying mechanisms by which PPAR can favorably modulate the expression of proliferative mediators in SCD-PH.
Academic Appointment
- Assistant Professor of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University School of Medicine
- Principle Investigator, Emory University
Education
Degrees
- PhD from Seoul National University
Research
Publications
-
ETV2/ER71 regulates hematovascular lineage generation and vascularization through an H3K9 demethylase, KDM4A.
iScience Volume: 28 Page(s): 111538
01/17/2025 Authors: Kim MS; Lee R; Lee DH; Song H; Ha T; Kim JK; Kang B-Y; Agger K; Helin K; Shin D -
Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis.
Front Immunol Volume: 16 Page(s): 1486784
01/01/2025 Authors: Ozuna H; Bojja D; Partida-Sanchez S; Hall-Stoodley L; Amer A; Britt RD; Sheikh S; Frank DA; Wang W; Kang B-Y -
PPAR/ETV2 axis regulates endothelial-to-mesenchymal transition in pulmonary hypertension.
Pulm Circ Volume: 14 Page(s): e12448
10/01/2024 Authors: Lee DH; Kim M; Chang SS; Lee R; Jang AJ; Kim J; Ma J; Passineau MJ; Benza RL; Karmouty-Quintana H -
3'UTR shortening of HAS2 promotes hyaluronan hyper-synthesis and bioenergetic dysfunction in pulmonary hypertension.
Matrix Biol Volume: 111 Page(s): 53 - 75
08/01/2022 Authors: Tseng V; Collum SD; Allawzi A; Crotty K; Yeligar S; Trammell A; Ryan Smith M; Kang B-Y; Sutliff RL; Ingram JL -
Circular RNA Expression in the Lungs of Sickle Cell Disease Mice
Volume: 35
05/01/2021 Authors: Sueblinvong V; Chang S; Park C; Benza R; Archer D; Sutliff R; Hart C; Kang B-Y -
PPAR increases HUWE1 to attenuate NF-B/p65 and sickle cell disease with pulmonary hypertension.
Blood Adv Volume: 5 Page(s): 399 - 413
01/26/2021 Authors: Jang AJ; Chang SS; Park C; Lee C-M; Benza RL; Passineau MJ; Ma J; Archer DR; Sutliff RL; Hart CM -
MicroRNA-98 reduces nerve growth factor expression in nicotine-induced airway remodeling.
J Biol Chem Volume: 295 Page(s): 18051 - 18064
12/25/2020 Authors: Wongtrakool C; Ko J; Jang AJ; Grooms K; Chang S; Sylber C; Kosmider B; Bahmed K; Blackburn MR; Sutliff RL -
MicroRNA-98 reduces nerve growth factor expression in nicotine-induced airway remodeling.
J Biol Chem Volume: 295 Page(s): 18051 - 18064
12/25/2020 Authors: Wongtrakool C; Ko J; Jang AJ; Grooms K; Chang S; Sylber C; Kosmider B; Bahmed K; Blackburn MR; Sutliff RL -
HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.
Sci Rep Volume: 10 Page(s): 11696
07/16/2020 Authors: Almodovar S; Wade BE; Porter KM; Smith JM; Lopez-Astacio RA; Bijli K; Kang B-Y; Cribbs SK; Guidot DM; Molehin D -
Integrative Analysis of Long Non-Coding RNAs and mRNAs in Lungs of Sickle Cell Mice
Volume: 34
04/01/2020 Authors: Kang B-Y; Chang S; Park C; Archer D; Sutliff R; Hart C